ValiRx Collaborates with German Cancer Research Center
ValiRx entered into a collaboration agreement with the Deutsches Krebsforschungzentrum cancer research center.
ValiRx, a life-science company with a focus on cancer diagnostics and therapeutics for personalized medicine, entered into a collaboration agreement with the Deutsches Krebsforschungzentrum (DKFZ), a German cancer research center, for the further development of ValiRx’s proprietary Gene Inactivation through Chromatin Engineering (GeneICE) technology platform. The goal of the research is to develop new targeting technologies that will improve the early detection and diagnosis of various cancers and new GeneICE compounds aimed at enhancing treatment outcomes.
The agreement builds on the ValiRx-DKFZ association announced in August 2013 by expanding the scope of the research to cover a wider range of activities relating to the development of the GeneICE technology and its use in the treatment of cancer, as well as its diagnostic and research applications. The agreement is aimed at accelerating the translation of the preclinical evidence supporting the GeneICE technology’s potential to silence specific "rebellious genes" implicated in causing cancers, and take individualized cancer medicine from bench to bedside.
Source: ValiRx
EMA Recommends Imfinzi-Based Perioperative Regimen for Treating Resectable NSCLC
March 10th 2025The committee’s recommendation is based on results from a Phase III trial in which Imfinzi demonstrated a reduced risk of recurrence, progression, or death by 32% compared to neoadjuvant chemotherapy alone.
International Women’s Day 2025: A Promising Future for Gender Diversity in Pharma
March 8th 2025In an interview with BioPharm International®, Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
